Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy

Johan Vansteenkiste, Primo N. Lara, Thierry Le Chevalier, Jean Luc Breton, Philip Bonomi, Alan B. Sandler, Mark A. Socinski, Catherine Delbaldo, Brent McHenry, David Lebwohl, Ronald Peck, Mark Edelman

Research output: Contribution to journalArticle

96 Scopus citations

Abstract

Purpose: Ixabepilone is the first in a new class of antineoplastic agents, the epothilones and their analogs. This international, randomized, phase II trial assessed two administration schedules of ixabepilone as second-line therapy in patients with non-small-cell lung cancer (NSCLC). Patients and Methods: Patients had experienced disease progression after one prior cisplatin- or carboplatin-based chemotherapy regimen. Ixabepilone was administered as a single 32 mg/m2 3-hour infusion (77 patients; arm A) or a 6 mg/m 2 1-hour infusion daily for 5 consecutive days (69 patients; arm B) in a 3-week cycle. Results: The intent-to-treat objective response rate was 14.3% in arm A and 11.6% in arm B. Median duration of response was 8.7 months (95% CI, 5.3 to 9.5 months) in arm A and 9.6 months (95% CI, 6.1 to 19.7 months) in arm B. Median time to progression was 2.1 months (95% CI, 1.4 to 2.8 months) for arm A and 1.5 months (95% CI, 1.4 to 2.8 months) for arm B. Median survival was 8.3 months (95% CI, 5.8 to 11.5 months) for arm A, and 7.3 months (95% CI, 5.7 to 11.7 months) for arm B; the 1-year survival rate (both cohorts) was 38%. Responses occurred in patients with taxane-pretreated and platinum-refractory tumors. Both regimens had an acceptable toxicity profile. Myelosuppression was manageable, manifesting primarily as neutropenia and leukopenia. Neuropathy was primarily sensory, generally mild to moderate in severity, and mostly reversible (both regimens). Conclusion: Single-agent ixabepilone had clinically relevant activity and an acceptable safety profile in patients with advanced NSCLC whose tumors had failed one prior platinum-based chemotherapy regimen.

Original languageEnglish (US)
Pages (from-to)3448-3455
Number of pages8
JournalJournal of Clinical Oncology
Volume25
Issue number23
DOIs
StatePublished - Aug 10 2007

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Vansteenkiste, J., Lara, P. N., Le Chevalier, T., Breton, J. L., Bonomi, P., Sandler, A. B., Socinski, M. A., Delbaldo, C., McHenry, B., Lebwohl, D., Peck, R., & Edelman, M. (2007). Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. Journal of Clinical Oncology, 25(23), 3448-3455. https://doi.org/10.1200/JCO.2006.09.7097